Sensex
79,809.65 profit arw -270.92 (-0.34%)
Nifty
24,426.85 profit arw -74.05 (-0.30%)
Nasdaq
18,355.20 profit arw -497.09 (-2.64%)
logo img

GET IN TOUCH

GET IN TOUCH

Refresh Captcha
Equity

As on : 28-Aug-2025
Hot Pursuit
28-Aug-2025     09:43

Biocon arm gets USFDA nod for Sitagliptin tablets

Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions like diabetes, cancer, and autoimmune diseases.

The company reported a 95.2% decline in consolidated net profit to Rs 31.40 crore despite of 15.8% jump in net sales to Rs 3,910.10 crore in Q1 FY26 over Q1 FY25.

Shares of Biocon rose 0.31% to Rs 359.70 on the BSE.

Powered by Capital Market - Live News

INDIAN INDICES

Sensex

79,809.65 -270.92 (-0.34%)

Nifty

24,426.85 -74.05 (-0.30%)

GLOBAL INDICES

USD

NA

NASDAQ
HANG SENG

25,077.63 78.80(0.32%)